A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 27, Issue 1, 2014, Pages 7-13

  Hod, Moshe ^a   Mathiesen, Elisabeth R ^b,c   Jovanovič, Lois ^d   McCance, David R ^e   Ivanisevic, Marina ^f   Durán Garcia, Santiago ^g   Brondsted, Lise ^h   Nazeri, Avideh ^h   Damm, Peter ^b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

^f KBC Zagreb   (Croatia)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h NOVO NORDISK A S   (Denmark)

Author keywords

Congenital malformations; Insulin detemir; Perinatal outcomes; Pregnancy; Type 1 diabetes

Indexed keywords

INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FETUS DISTRESS; FETUS WASTAGE; GESTATIONAL AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERINATAL DEATH; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ABORTION, INDUCED; ABORTION, SPONTANEOUS; CONGENITAL ABNORMALITIES; DIABETES MELLITUS, TYPE 1; DRUG COMBINATIONS; FEMALE; FETAL DEATH; GESTATIONAL AGE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; LIVE BIRTH; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; PREGNANCY, ECTOPIC;

EID: 84889651836     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2013.799650     Document Type: Article

References (30)

1. MacIntosh MCM, Fleming KM, Bailey JA, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales and Northern Ireland: Population based study. BMJ 2006;333:177-80
2. Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetes pregnancies. Diabetes Care 2004;27:2819-23
3. Evers IM, de Valk HW, Visser GHA. Risk of complications of pregnancy in women with type 1 diabetes: Nationwide prospective study in the Netherlands. BMJ 2004;328:915-19
4. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 2000;43:79-82
5. Nielsen GL, Sorensen HT, Nielsen PH, et al. Glycosylated hemoglobin as predictor of adverse fetal outcome in type 1diabetic pregnancies. Acta Diabetol 1997;34:217-22
6. DCCT Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996;174: 1343-53
7. Murphy HR, Rayman G, Duffield K, et al. Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy. Diabetes Care 2007;30:278-91
8. Confidential Enquiry into Maternal and Child Health (CEMACH). Pregnancy in women with type 1 and type 2 diabetes in 2002-2003, England, Wales and Northern Ireland. London: CEMACH; 2005
9. Casson IF. Pregnancy in women with diabetes - After the CEMACH report, what now? Diabet Med 2006;23:481-4
10. Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of longterm blood glucose control in type 1 diabetes mellitus: A randomized controlled trial. Diabet Med 2000;17:762-70
11. Rosenstock J, Schwartz SL, Clark Jr CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6
12. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47: 622-9
13. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-Term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-Totarget basal-bolus regimen with insulin aspart at meals: A 2-year, randomized, controlled trial. Diabet Med 2008;25:442-9
14. Mathiesen ER, Kinsley B, Amiel SA, et al Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30:771-6
15. Mathiesen ER, Damm P, Jovanovic L, et al. Basal insulin analogues in diabetic pregnancy: A literature review and baseline results of a randomised, controlled trial in type 1 diabetes. Diabetes Metab Res Rev 2011;27:543-51
16. Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes mellitus. Diabetes Care 2012;35:2012-17
17. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53: 1614-20
18. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-Action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-9
19. Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36
20. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basalbolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7:73-82
21. Kølendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006;23:729-35
22. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-To-Target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29:1269-74
23. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
24. Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: The PREDICTIVE BMI clinical trial. Diabet Med 2008;25:916-23
25. Hod M, Damm P, Kaaja R, et al Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: A randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008;198:186.e1-7
26. Penney GC, Mair G, Pearson DW, Scottish Diabetes in Pregnancy Group. Outcomes of pregnancies in women with type 1 diabetes in Scotland: A national population-based study. BJOG 2003;110: 315-18
27. Bell R, Bailey K, Cresswell T, et al Northern Diabetic Pregnancy Survey Steering Group. Trends in prevalence and outcomes of pregnancy in women with pre-existing type I and type II diabetes. BJOG 2008;115:445-52
28. Lisi A, Botto LD, Robert-Gnansia E, et al. Surveillance of adverse fetal effects of medications (SAFE-Med): Findings from the International Clearinghouse of Birth Defects Surveillance and Research. Reprod Toxicol 2010;29:433-42
29. Novo Nordisk. Levemir prescribing information. 2012. Available from: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 021536s037lbl.pdf [last accessed 1 Oct 2012].
30. Novo Nordisk. Levemir summary of product characteristics. 2012. Available from: Http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product- Information/human/000528/ WC500036662.pdf [last accessed 1 Oct 2012].